Tivozanib monotherapy in the frontline setting for patients with metastatic renal cell carcinoma and favorable prognosis (vol 26, pg 1639, 2024)

Item

Tivozanib monotherapy in the frontline setting for patients with metastatic renal cell carcinoma and favorable prognosis (vol 26, pg 1639, 2024)

Frazer, R.
;
Arranz, J. A.
;
Estévez, S. V.
;
Parikh, O.
;
Krabbe, L. M.
;
Vasudev, N. S.
;
Doehn, C.
;
Marschner, N.
;
Waddell, T.
;
Ince, W.
... show 1 more

Citations

Google Scholar:

Altmetric:

Authors

Frazer, R.
Arranz, J. A.
Estévez, S. V.
Parikh, O.
Krabbe, L. M.
Vasudev, N. S.
Doehn, C.
Marschner, N.
Waddell, T.
Ince, W.
Goebell, P. J.

Affiliation

Velindre Canc Ctr, Cardiff CF14 2TL, Wales Hosp Gen Univ Gregorio Maranon, Madrid, Spain Hosp Univ Lucus Augusti HULA, Lugo, Spain Lancashire Teaching Hosp NHS Fdn Trust, Chorley, England Vivantes Humboldt Klinikum, Klin Urol, Berlin, Germany Leeds Inst Med Res St JamesS, Leeds, England Urologikum Lubeck, Lubeck, Germany Clin Res Inst IOMEDICO, Freiburg, Germany Christie NHS Fdn Trust, Manchester, England Cambridge Univ NHS Fdn Trust, Dept Oncol, Cambridge, England Uniklin Erlangen, Urol & Kinderurol Klin, Erlangen, Germany

Date

2025

Collections

All Christie Publications

Show all metadata

Files

Found from Unpaywall

Adobe PDF, 636.2 KB

Type

Article

Citation

Frazer R, Arranz JA, Estévez SV, Parikh O, Krabbe LM, Vasudev NS, et al. Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis (vol 26, pg 1639, 2024). CURRENT ONCOLOGY REPORTS. 2025 JUN;27(6):788-90. PubMed PMID: WOS:001484802700001. English.

URI

https://christie.openrepository.com/handle/10541/628199